Drug profile · INN
macitentan
OPSUMIT
macitentan (OPSUMIT) is a endothelin receptor, et-a/et-b antagonist. Associated with Janssen-Cilag Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — macitentan
- US status
- approved
- Class
- Cardiovascular system (C02)
- Route
- ORAL
- Patents
- 0
- Programs
- 6
- Data quality
- 0.84
Quick answer
macitentan (OPSUMIT) is a endothelin receptor, et-a/et-b antagonist. Associated with Janssen-Cilag Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Endothelin receptor, ET-A/ET-B antagonist
Primary target: Endothelin receptor, ET-A/ET-B
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is macitentan?
macitentan (OPSUMIT) is a endothelin receptor, et-a/et-b antagonist. Associated with Janssen-Cilag Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for macitentan?
OPSUMIT is a marketed brand name for macitentan. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of macitentan?
macitentan has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.